CHEST 2022
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
ACAAI 2022
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
ACAAI 2022
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
CHEST 2022
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
CHEST 2022
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
CHEST 2022
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
AAAAI 2022
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
AAAAI 2022
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?
